

Megan J Munsie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8898989/publications.pdf>

Version: 2024-02-01

52
papers

2,107
citations

361413

20
h-index

243625

44
g-index

56
all docs

56
docs citations

56
times ranked

2041
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing a Reflexive, Anticipatory, and Deliberative Approach to Unanticipated Discoveries: Ethical Lessons from iBlastoids. <i>American Journal of Bioethics</i> , 2022, 22, 36-45.	0.9	13
2	Response to Open Peer Commentaries on “Developing a Reflexive, Anticipatory, and Deliberative Approach to Unanticipated Discoveries: Ethical Lessons from iBlastoids” <i>American Journal of Bioethics</i> , 2022, 22, W1-W3.	0.9	1
3	The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy. <i>Cytotherapy</i> , 2022, , .	0.7	1
4	From the margins to mainstream: How providers of autologous “stem cell treatments” legitimise their practice in Australia. <i>Health (United Kingdom)</i> , 2021, 25, 51-68.	1.5	5
5	Regulating autologous stem cell interventions in Australia: updated review of the direct-to-consumer advertising restrictions. <i>Australian Health Review</i> , 2021, 45, 507-515.	1.1	2
6	Academic physician specialists’ views toward the unproven stem cell intervention industry: areas of common ground and divergence. <i>Cytotherapy</i> , 2021, 23, 348-356.	0.7	9
7	ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. <i>Stem Cell Reports</i> , 2021, 16, 1398-1408.	4.8	134
8	Ethical issues and public communication in the development of cell-based treatments for COVID-19: Lessons from the pandemic. <i>Stem Cell Reports</i> , 2021, 16, 2567-2576.	4.8	9
9	Academic Physician Specialists’ Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapies” A Qualitative Analysis. <i>Mayo Clinic Proceedings</i> , 2021, 96, 3086-3096.	3.0	4
10	Australian regulation of autologous human cell and tissue products: implications for commercial stem cell clinics. <i>Regenerative Medicine</i> , 2020, 15, 1361-1369.	1.7	7
11	The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients. <i>Regenerative Medicine</i> , 2020, 15, 1238-1249.	1.7	9
12	Toward Guidelines for Research on Human Embryo Models Formed from Stem Cells. <i>Stem Cell Reports</i> , 2020, 14, 169-174.	4.8	63
13	Section 3: Locus of Care. , 2020, , 135-180.		0
14	Navigating the cartographies of trust: how patients and carers establish the credibility of online treatment claims. <i>Sociology of Health and Illness</i> , 2019, 41, 50-64.	2.1	11
15	Citizens’ use of digital media to connect with health care: Socio-ethical and regulatory implications. <i>Health (United Kingdom)</i> , 2019, 23, 367-384.	1.5	16
16	The politics of evidence in online illness narratives: An analysis of crowdfunding for purported stem cell treatments. <i>Health (United Kingdom)</i> , 2019, 23, 436-457.	1.5	16
17	Contact us for more information: an analysis of public enquiries about stem cells. <i>Regenerative Medicine</i> , 2019, 14, 1137-1150.	1.7	10
18	Debate ethics of embryo models from stem cells. <i>Nature</i> , 2018, 564, 183-185.	27.8	72

#	ARTICLE	IF	CITATIONS
19	Ethical issues in genetic modification and why application matters. <i>Current Opinion in Genetics and Development</i> , 2018, 52, 7-12.	3.3	15
20	The current state of stem cell therapy for ocular disease. <i>Experimental Eye Research</i> , 2018, 177, 65-75.	2.6	24
21	A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore. <i>Cytotherapy</i> , 2018, 20, 1103-1109.	0.7	9
22	Stem Cell Tourism and the Political Economy of Hope. , 2017, , .		49
23	Ethical issues in human organoid and gastruloid research. <i>Development (Cambridge)</i> , 2017, 144, 942-945.	2.5	80
24	The deadly business of an unregulated global stem cell industry. <i>Journal of Medical Ethics</i> , 2017, 43, 744-746.	1.8	36
25	The European General Data Protection Regulation: challenges and considerations for iPSC researchers and biobanks. <i>Regenerative Medicine</i> , 2017, 12, 693-703.	1.7	33
26	Marketing of unproven stem cellâ€‘based interventions: A call to action. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	147
27	Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan. <i>Regenerative Medicine</i> , 2017, 12, 777-790.	1.7	34
28	â€‘No one here's helping me, what do you do?â€™: addressing patient need for support and advice about stem cell treatments. <i>Regenerative Medicine</i> , 2017, 12, 791-801.	1.7	18
29	The Immortal Life of Ethics? The Alienation of Body Tissue, Ethics and the Informed Consent Procedure Within Induced Pluripotent Stem Cell Research. , 2017, , 61-87.		1
30	Stem Cell Tourism in Context. , 2017, , 1-29.		2
31	Regulating the stem cell industry: needs and responsibilities. <i>Bulletin of the World Health Organization</i> , 2017, 95, 663-664.	3.3	14
32	Managing Hope. , 2017, , 59-82.		0
33	Hope â€‘at Homeâ€™: Stem Cell Treatments in Australia. , 2017, , 155-184.		0
34	Re-framing â€‘Stem Cell Tourismâ€™. , 2017, , 185-202.		0
35	An Interactive Multimedia Approach to Improving Informed Consent for Induced Pluripotent Stem Cell Research. <i>Cell Stem Cell</i> , 2016, 18, 307-308.	11.1	37
36	Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. <i>Stem Cell Reports</i> , 2016, 6, 787-797.	4.8	172

#	ARTICLE	IF	CITATIONS
37	Participant understanding and recall of informed consent for induced pluripotent stem cell biobanking. <i>Cell and Tissue Banking</i> , 2016, 17, 449-456.	1.1	20
38	Stem cell miracles or Russian roulette?: patients' use of digital media to campaign for access to clinically unproven treatments. <i>Health, Risk and Society</i> , 2016, 17, 592-604.	1.7	21
39	Between hope and evidence: How community advisors demarcate the boundary between legitimate and illegitimate stem cell treatments. <i>Health (United Kingdom)</i> , 2015, 19, 188-206.	1.5	32
40	What if stem cells turn into embryos in a dish?. <i>Nature Methods</i> , 2015, 12, 917-919.	19.0	59
41	Regulatory Loophole Enables Unproven Autologous Cell Therapies to Thrive in Australia. <i>Stem Cells and Development</i> , 2014, 23, 34-38.	2.1	26
42	Therapeutic journeys: the hopeful travails of stem cell tourists. <i>Sociology of Health and Illness</i> , 2014, 36, 670-685.	2.1	89
43	Managing the potential and pitfalls during clinical translation of emerging stem cell therapies. <i>Clinical and Translational Medicine</i> , 2014, 3, 10.	4.0	37
44	A question of ethics: Selling autologous stem cell therapies flaunts professional standards. <i>Stem Cell Research</i> , 2014, 13, 647-653.	0.7	41
45	Seeing the Full Picture: The Hidden Cost of the Stem Cell and Regenerative Medicine Revolution. <i>Pancreatic Islet Biology</i> , 2014, , 291-304.	0.3	1
46	Isolation and Production of Cells Suitable for Human Therapy: Challenges Ahead. <i>Cell Stem Cell</i> , 2009, 4, 20-26.	11.1	132
47	New ISSCR Guidelines Underscore Major Principles for Responsible Translational Stem Cell Research. <i>Cell Stem Cell</i> , 2008, 3, 607-609.	11.1	218
48	Transgenic Systems in Nuclear Reprogramming. , 2006, 325, 115-128.		0
49	Transgenic Strategy for Demonstrating Nuclear Reprogramming in the Mouse. <i>Cloning and Stem Cells</i> , 2002, 4, 121-130.	2.6	9
50	Isolation of pluripotent embryonic stem cells from reprogrammed adult mouse somatic cell nuclei. <i>Current Biology</i> , 2000, 10, 989-992.	3.9	352
51	Novel method for demonstrating nuclear contribution in mouse nuclear transfer. <i>Reproduction, Fertility and Development</i> , 1998, 10, 633.	0.4	11
52	Pulling the plug on the stem cell hype. <i>Medical Journal of Australia</i> , 0, , .	1.7	0